Introduction
STAT3, a member of the STAT (signal transducer and activator of transcription) family, has received considerable attention for the important role it plays in signaling pathways linked to inflammation-associated diseases and cancers (1) . Notably, unlike the transient activation of STAT3 characteristic of normal cells, STAT3 tends to be constitutively activated in most cancer cells. In these cells, STAT3 is associated with tumorigenesis and malignancy because its downstream signaling results in production of a number of cytokines that regulate proliferation, angiogenesis, survival, and metastasis (2) . For these reasons, many research groups have focused on developing inhibitors that can block upstream or downstream elements in the STAT3 signaling pathway (3, 4) .
Upon activation, STAT3 becomes phosphorylated and undergoes dimerization. The active, dimeric form enters the nucleus, where it binds to target DNA-response elements, leading to the expression of proteins related to cancer progression and malignancy. Thus, inhibitors reported to date, including small molecules (5-9), decoy oligodeoxynucleotides (ODNs) (10) , siRNAs (11) , and peptides (12, 13) and their peptidomimetics (14, 15) , target one of the key steps required for STAT3-mediated gene expression. Several small molecules that can inhibit phosphorylation and subsequent dimerization by binding to the SH2 domain of STAT3 have been shown to suppress cancer cell growth in vitro and reduce tumor burden in vivo, and indeed a few such inhibitors are now in various phases of clinical trials (3) . Decoy ODNs that can intercept the active form of the STAT3-dimer also show potential as inhibitors in in vivo tumor models (16) . Peptide-based STAT3 inhibitors have also been reported. These inhibitory phospho-peptides (P*YLKTK, Y*LPQTV), based on a truncated gp130 sequence, bind to the SH2 domain of STAT3 and block dimerization (17, 18) . However, the relatively low potency and limited cell permeability of such phospho-peptides have hampered their further use in an in vivo setting. Peptide libraries have been screened for interaction with the DNA-binding domain of STAT3, and the identified peptides have been shown to inhibit STAT3 DNA-binding activity (19) . Very recently, a short peptide derived from the helices of the N-terminal domain of STAT3 has been shown to inhibit STAT3 transcriptional activity (20) . However, although these peptide inhibitors have shown cytotoxicity in various cancer cells by blocking STAT3 signaling, to date there have been few reports demonstrating antitumor efficacy in vivo (3, 21) .
Aptides, developed by our laboratory, constitute a platform technology that enables screening and identification of high-affinity and -specificity peptides for various biological targets (22) . An aptide consists of a tryptophan zipper scaffold that forms a robust β-hairpin structure and a target-binding site containing 12 randomizable amino acids that enables library construction (Fig. 1A) . Phage display of an aptide library has enabled us to identify a number of aptides specific to various protein targets (22) . Most such aptides showed affinities in the tens-of-nanomolar range, even before affinity maturation, and as such represent a general source of high-affinity binders. Here, we report the screening and identification of a STAT3-specific aptide (APT STAT3 ) and evaluate its potential as an inhibitor of STAT3 signaling in cancer cells in vitro and in tumor-bearing mice in vivo. To the best of our knowledge, APT STAT3 is the first reported peptide inhibitor to show therapeutic efficacy in in vivo animal models by blocking STAT3 activation. 
Materials and Methods

Cell lines and culture
The A549 human lung carcinoma, B16F1 mouse melanoma, HepG2 human hepatocellular carcinoma, MDA-MB-231 breast cancers, and U87MG human neuronal glioblastoma cells were obtained from the American Type Culture Collection (ATCC).
A549 cells were maintained in Ham's F12K. B16F1 and MDA-MD-231 cells were maintained in RPMI 1640 medium. HepG2 cells were maintained in DMEM medium.
U87MG cells were maintained in MEM medium. The cell culture media were supplemented with 10% heat-inactivated FBS.
Materials
All peptides, including APT STAT3 -9R and APR scr -9R, were custom-synthesized by AnyGen (Jeonnam, South Korea). STAT3 protein was obtained from SignalChem.
Antibodies against STAT3, STAT1, STAT5, phosphorylated STAT3 (P-STAT3), P-STAT5, P-STAT1 AKT, P-AKT, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Bcl-xL, survivin and cyclin D1 were obtained from Cell Signaling.
Screening and identification of STAT3-specific binders
A STAT3-specific aptide was identified using a phage display-based screening method, as described previously (22) . Briefly, STAT3 was immobilized on 96-well plates (Corning) overnight at 4°C. After incubating phage library pools on STAT3-immobilized plates for 1 h at 25°C, unbound phages were removed by washing with phosphate-buffered saline (PBS) containing 0.5% Tween-20 (PBS-T), and bound phages were eluted with 0.2 M glycine buffer (pH 2. 
DNA-binding assay
Following treatment of cells with APT STAT3 -9R, APR scr -9R or PBS for 6 h, cell extracts were prepared and analyzed for STAT3 DNA-binding activity in triplicate using a TransAM STAT3 transcription factor assay kit, following the manufacturer's protocol (Active Motif).
Quantitative reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated using Ribo EX (GeneAll) and subjected for reverse transcription using Reverse Transcriptase (Promega) according to the manufacturer's instructions. Quantitative real-time PCR were carried out as described (23) .
Western blot analysis
Cell lysates were prepared in PRO-PREP TM protein extraction solution. 
Cell viability assay
Cells were plated in a 96 well plate (5000 cells per well) and incubated for 12 h.
After incubation the cells were treated with 9R, APT STAT3 -9R and APR scr -9R for 12 h.
After 12 h incubation, 20 μL MTT (5 mg/mL) was added to each well. After 4 h, 100
μL DMSO was added to each well, and absorbance was measured at 570 nm using a Spectra Macplus microplate reader (Molecular Devices).
Colony-formation assay
Cells in growth medium were cultured at 500 cells/well in 12-well plates and treated with APT STAT3 -9R, APR scr -9R, or PBS on the following day. Cells were then allowed to grow for 2 wk until colonies were visible. Colonies were stained by incubating with 0.1% Coomassie Brilliant Blue R-250 for 20 min.
Flow cytometry analysis
The Annexin-V-FITC Apoptosis Detection Kit (BD Biosciences) was used to detect apoptosis by flow cytometry. Cells were exposed to APT STAT3 -9R, APR scr -9R, or PBS treatment at 30 μM, and after 6h, they were harvested (including detached cells), and processed according to the manufacturer's instructions. 
Statistical analysis
The statistical significance of differences among groups was calculated by one-way analysis of variance (ANOVA). A p-value < 0.001 was considered statistically significant.
Results and Discussion
A specific STAT3-binding peptide and its cell-permeable derivative
Using phage display of an aptide library, we were able to screen and identify a specific STAT3-binding peptide (Fig. 1A) . A total of four rounds of selection were performed to enrich for phage clones that showed specificity for STAT3 in phage ELISAs ( Supplementary Fig. 1 ). Sequencing of the bound phages yielded only an aptide sequence. The affinity and specificity of the identified STAT3-binding aptide (APT STAT3 ) were measured. A surface plasmon resonance assay revealed that APT STAT3 bound to STAT3 with a dissociation constant (K d ) of 231 nM; a control peptide containing the same trpzip scaffold but with a scrambled sequence in the target-binding site, APT scr , did not bind STAT3 (Supplementary Fig. 2 ). Phage ELISAs showed that the phage displaying APT STAT3 sequence was highly specific to the target STAT3 
compared to other proteins, whereas the phage displaying APT scr sequence showed no appreciable binding to any of the proteins tested (Fig. 1B) . To impart cell permeability to APT STAT3 , we fused APT STAT3 with a nine-arginine (9R), a cell-penetrating peptide (Fig. 1A) (24) . ELISAs using an anti-aptide mAb showed that APT STAT3 -9R was also able to specifically bind STAT3 with a comparable binding ability to APT STAT3 , as evidenced by a concentration-dependent increase in the ELISA signal, whereas the 9R-modified scrambled aptide (APT scr -9R) showed little signal enhancement (Fig. 1C) .
Next we examined whether the attachment of 9R to the aptides would enable cell penetration and thus intracellular localization. As clearly shown in 
DNA binding activity in A549 cells (Fig 2A) . This result suggests that APT STAT3 is not a just binder but an effector involved in inhibition of homo-or hetero-dimerization of phosphorylated STAT3. To further examine the inhibitory effect of APT STAT3 -9R on STAT3 downstream signaling, we measured mRNA expression of the STAT3 target genes, Cyclin D1, Bcl-xL and Survivin (10) , by quantitative RT-PCR. Treatment with APT STAT3 -9R decreased the mRNA levels of the indicated targets in a dose dependent manner in A549 cells, whereas APT scr -9R (30 μM) treatment had little effect (Fig. 2B) .
Next, we estimated the expression of these genes at the protein level by western blotting after treatments of A549 cells with APT STAT3 -9R (7.5, 15, and 30 μM) or APT scr -9R (30 μM) for 6 h. As shown in Fig. 2C , the expression level of each protein was markedly decreased by treatment with APT STAT3 -9R in a dose dependent manner compared to that in untreated controls. As expected, cells treated with non-relevant APT scr -9R showed no appreciable difference in the levels of these proteins compared with controls.
Furthermore, a similar trend of results was also obtained in various murine and human cancer cell lines, including B16F1, HepG2, MDA-MB-231, and U87MG that are known to express constitutively activated STAT3, confirming the inhibitory effect of APT STAT3 -9R on STAT3 downstream signaling ( Supplementary Fig. 3-5) . Interestingly, we found that APT STAT3 -9R effectively inhibited phosphorylation of STAT3 (Fig. 2D) but did not affect the level of AKT phosphorylation, indicating specificity of the aptide.
This suggests that APT STAT3 -9R may be able to suppress expression of STAT3-associated target genes by specifically inhibiting STAT3 phosphorylation. however, moderate binding to DBD was also observed (Supplementary Fig. 7A ). This finding suggests that the SH2 domain may be a putative binding site of the aptide.
Furthermore, to obtain a piece of clues regarding the mode-of-action of APT STAT3 we carried out a JAK2 kinase activity assay as the kinase is a key enzyme responsible for STAT phosphorylation. As illustrated in Supplementary Fig. 7B and 7C alone were estimated to be > 100 μM (Fig. 3A) . A similar level of IC 50 values was attained in B16F1 and HepG2 cells treated with APT STAT3 -9R ( Supplementary Fig. 3D and 4C). In addition, we carried out colony-formation assay to assess whether APT STAT3 -9R suppresses cancer cell proliferation. Proliferation of A549 and B16F1 cancer cells was monitored for 2 weeks after cell seeding (500 cells per well) in the presence of APT STAT3 -9R or APT scr -9R (30 μM). Colony formation was significantly suppressed in the APT STAT3 -9R-treated group but not in the APT scr -9R group (Fig 3B and Supplementary Fig. 3E ). Furthermore, we confirmed that APT STAT3 -9R treatment induced apoptosis of A549 cells by ~3-fold increase compared to APT scr -9R in flow cytometry assessment (Fig 3C) . Collectively, these results indicate that APT STAT3 -9R effectively suppresses cell survival and growth.
APT STAT3 -9R suppresses tumor growth in vivo
Encouraged by the potency of APT STAT3 -9R in inhibiting cell proliferation in vitro, we explored the antitumor efficacy of the aptide in vivo. A human lung carcinoma 
mg/kg) was intratumorally injected every other day for a total of four injections. Tumor burden was significantly reduced (~65% relative to the control) in the APT STAT3 -9R-treated group (Fig. 4A ) compared with that in the PBS control group; however, there was little difference in tumor size between APT scr -9R and PBS groups. Images of excised tumors at day 30 further indicate significant difference between the aptidetreated group and control groups (Fig. 4B) . We found that the amount of phosphorylated STAT3 in the excised tumor tissues of APT STAT3 -9R-treated group was substantially diminished, whereas APT scr -9R did not show any appreciable inhibition of STAT3 phosphorylation in the tumor tissues (Fig. 4C) . Furthermore, TUNEL assays on excised tumor tissues revealed that, unlike PBS or the scrambled aptide-treated groups, the APT STAT3 -9R-treated group showed a significant level of apoptosis in tumor sections, presumably due to inhibition of STAT3 activation and downstream signaling (Fig. 4D) .
In addition to A549 xenograft mice model, we also evaluated the anticancer efficacy of APT STAT3 -9R in two additional tumor models, B16F1 melanoma allograft and U87MG glioblastoma xenograft models. Since B16F1 melanoma tumor is known to be aggressive and rapidly grows, APT STAT3 -9R was injected to the same foot pad where the melanoma cells were implanted 2 days ago as suggested in the protocol published elsewhere (25) . The APT STAT3 -9R substantially reduced tumor burden by ~49% and thus extended survival time by more than 15 days compared to the control (PBS-treated) group (Supplementary Fig. 8 ). In the case of U87MG glioblastoma xenograft tumor model the first intratumoral injection of each group was initiated when the tumor volumes had reached ~120 mm 3 and terminated after a total of four times injection. The tumor growth was significantly inhibited by treatment of the STAT3-specific aptide but little inhibition was seen from the scrambled aptide-treated group (~45% versus ~7% Fig. 9 ). Collectively, these results indicate that APT STAT3 -9R could effectively suppress tumor growth in the in vivo allograft and xenograft tumor models by inhibiting STAT3 phosphorylation.
Conclusion
In summary, we screened and identified a specific STAT3-binding peptide (APT STAT3 ) using aptide platform technology. With the addition of a cell-penetrating motif, the resulting APT STAT3 -9R aptide was able to suppress the viability and 
